Apixaban Prophylactic Anticoagulation in Patients With Nephrotic Syndrome

Tess Van Meerhaeghe (✉ tess.van.meerhaghe@erasme.ulb.ac.be)

Erasmus Hospital

Alexandre Cez

Assistance Publique Hôpitaux de Paris, Hôpital Tenon

Karin Dahan

Assistance Publique Hôpitaux de Paris, Hôpital Tenon

Emmanuel Esteve

Assistance Publique Hôpitaux de Paris, Hôpital Tenon

Ismail Elalamy

Assistance Publique Hôpitaux de Paris, Hôpital Tenon

Jean Jacques Boffa

Assistance Publique Hôpitaux de Paris, Hôpital Tenon

Eleonore Ponlot

Grand Hôpital de Charleroi GHDC

Research Article

Keywords: Nephrotic syndrome, anticoagulation, direct oral anticoagulants, thromboembolic event, thromboprophylaxis, hypoalbuminemia.

Posted Date: September 17th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-730015/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Nephrotic syndrome (NS) is associated with an increased risk of thromboembolic events (TE), due to hemostatic derangements. The use of direct oral anticoagulants (DOAC) in the prevention of TE hasn't been studied intensively in patients suffering from NS.

Methods

Retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thrombophylaxis. It is an uncontrolled, single center study.

Results

We identified 27 patients treated with apixaban for the prevention of TE, in the context of NS. During follow-up apixaban Cmin and Cmax levels were measured. The mean duration of the anticoagulant treatment was 153 days (± 132). Patients were followed for a mean of 14.7 months (± 8.4) since the introduction of apixaban. Three patients had a TE at the time of NS diagnosis. Two patients had pulmonary embolism (PE) and one patient presented a stroke in lupus membranous nephropathy context. One patient developed PE approximately 2 months after introduction of apixaban treatment. No minor nor major bleeding events were noticed.

Conclusion

The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had reduced risk of venous and arterial TE compared to patients previously described in the literature, without increased risk of bleeding.

Introduction

Nephrotic syndrome (NS) is characterized by heavy proteinuria and hypoalbuminemia. Patients with NS are known to have a prothrombotic state with an increased risk of thromboembolic events (TE). The hemostatic derangements are not completely understood, but urinary losses of anticoagulant proteins may play an important role¹. The estimated prevalence of thromboembolic disease can increase up to 37% in this specific population.¹

Moreover the risk of thromboembolism may be influenced by the type of glomerular disease (membranous nephropathy being at higher risk, estimated at 37%), the duration of the NS and the severity

evaluated by serum albumin and proteinuria levels.^{2,3,4} The majority of venous TE occur within the first 6 months after NS diagnosis.⁵

Some studies support the use of prolonged thromboprophylaxis strategy in NS patients.^{6–8} While classically warfarin has been used as an anticoagulant in NS, direct oral anticoagulants (DOACs), such as apixaban, are increasingly used to treat arterial or venous thrombosis in the general population. However the efficacy and safety of DOACs in patients with NS has not been evaluated in large randomized controlled trials. Evidence is mostly based on case reports and case series.^{9–13}

Routine therapeutic monitoring of plasma Anti-Xa activity is not required because of the drug's predictability and its wide therapeutic index. Despite the use of fixed doses of apixaban, determination of the amount of drug present in a given individual may be of interest in some vulnerable and instable clinical situations, such as pre-operative setting, bleeding episode, complex comorbidities, extreme body weight or elderly patients.¹⁴ Hypoalbuminemia itself can lead to altered pharmacokinetics and pharmacodynamics of medications, although this topic is infrequently considered in daily clinical practice.¹⁵

The aims of our study were to evaluate the efficacy of apixaban to prevent TE in patients with NS and to determine the interest of drug monitoring in these frail patients.

Materials And Methods

Design

We conducted a retrospective analysis of consecutive incident patients with NS due to glomerular disease, receiving apixaban for thromboprophylaxis. It is an uncontrolled, single center study. The patients were included from September 2018 to October 2020. All patients consented to participate to the study.

NS was defined by the presence of an urinary protein excretion greater than 3g/day or as a protein/creatinine ratio of > 3 g/g on urinary spot in association with hypoalbuminemia < 30 g/L.

Patients who were already treated with anticoagulants at NS onset for another indication or with formal contra-indication for anticoagulants were excluded.

All thromboembolic events were recorded at onset of NS and during follow-up, as well as minor and major bleeding events.

Intervention

Patients were systematically treated with Apixaban when albumin levels dropped below 20 g/L or below 25 g/l for patients suffering from membranous nephropathy.

Patients were treated with a classical regimen of apixaban 5 mg twice daily. In patients fulfilling at least two (2) of the following criteria, a reduced dose of apixaban 2.5 mg twice daily was used: age $\geq$ 80 years, body weight $\leq$ 60 kg, or serum creatinine $\geq$ 133 micromol/L (1.5 mg/dL). Using liquid chromatography/tandem mass spectrometry, Apixaban trough Cmin and Cmax levels (2h after ingestion) were measured.

Outcome

Baseline characteristics and outcomes were identified from patients' records. Baseline characteristics included demographics, plasma albumin, plasma creatinine, estimated glomerular filtration rate (eGFR) according to CKD-Epi, low density lipoprotein (LDL) cholesterol, hemoglobin level, anti-Xa apixaban level, urine protein excretion, and type of glomerular disease. Blood and urine parameters were measured using automated, standardized biological assays. The parameters recorded were measured the same day as apixaban level if available. TE were identified from patients' records and included pulmonary embolism (PE), deep vein thrombosis (DVT), renal vein thrombosis (RVT) and stroke.

Statistics

Data were described using mean $\pm$ standard deviation (SD) or medians and interquartile ranges (IQR) 25–75 depending on the distribution.

Results

The baseline characteristics are shown in Table 1. A total of 27 consecutive patients were included in the study and 59% were men. Six patients were active smokers, three suffered from diabetes, and eleven had arterial hypertension before NS onset. The mean age at time of treatment with apixaban was 45.4 years ($\pm$ 18.3). The mean serum creatinine level was 106.3 ($\pm$ 44.7) μ mol/L (Normal range between 74.3–107 μ mol/L). 67% of the patients had an eGFR according to CKD-EPI above 60 ml/min, 11% suffered from chronic kidney disease (CKD) stage 3a, 18% had a CKD stage 3b and only one patient had CKD stage 4 according to the KDIGO classification criteria. The mean serum albumin was 15.8 g/L ($\pm$ 4.7) (Normal range between 35–50 g/L), and the median urinary P/C ratio was 7.3 g/g [4.3–10.2] (Normal P/C < 0.2 g/g).

Six patients presented minimal change disease (MCD), three had the histological diagnosis of focal segmental glomerulosclerosis (FSGS), eleven had anti-PLA2R positive membranous nephropathy (MN), two had anti-PLA2R negative MN and five suffered from lupus MN. No woman was pregnant or under contraceptive treatment at the time of NS diagnosis.

The mean duration of the anticoagulant treatment was 153 days ($\pm$ 132). Patients were followed for a mean of 14.7 months ($\pm$ 8.4) since the introduction of apixaban. Of note three patients had a thromboembolic event at the time of NS diagnosis. Two patients had PE and one patient presented a stroke in lupus MN context. One patient developed PE approximately 2 months after introduction of apixaban treatment. He suffered from a genetic form of FSGS. Unfortunately, apixaban levels were not

measured for this patient at that time. Only one patient was concomitantly treated with Aspirin with no bleeding tendency.

Figure 1 and 2 report Apixaban Cmin and Cmax determination. Data are missing for 3 patients. Of note 1 patient had only Cmin level measured and 4 patients only Cmax. No minor or major bleeding events were recorded during the follow-up period. Kidney function remained stable during follow-up.

Table 1
Baseline data

Number of patients	27
Male (%)	16 (59%)
Smoking (%)	6 (22%)
Diabetes type 2	3 (11%)
Arterial hypertension	11 (41%)
Mean age in years	45.4 (± 18.3)
Mean serum creatinine in µmol/l	106.3 (± 44.7)
Mean serum albumin in g/l	15.8 (4.7)
Median protein/creatinine ratio in g/g [IQR 25–75]	7.3 [4.3–10.2]
Mean LDL cholesterol level in g/l	2.64 (± .0.8)
Mean duration of treatment in days	153 (± 132)
Number of patients treated with 5 mg APIXABAN twice daily	20 (74%)
Mean follow-up time in months since start of treatment with APIXABAN	14.7 (± 8.4)
Renal function (eGFR according to CKD-Epi)	18 (67%)
eGFR > 60 ml/min	3 (11%)
eGFR 45–59 ml/min	5 (18%)
eGFR 30–44 ml/min	1 (4%)
eGFR 15–29 ml/min	0
eGFR < 15 ml/min	
Patients with venous or arterial TE before start of anticoagulation	3 (11.1%)
Patients developing TE during follow-up	1 (3.7%)
Use of contraceptive treatment	0

Discussion

The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had reduced risk of venous and arterial thromboembolism compared to patients previously described in the literature, without increased risk of bleeding.

The direct-acting oral anticoagulants (DOACs) have many advantages over warfarin. In particular, apixaban has rapid onset (1–3 h) and offset (half-life 8–15 h) of action, with predictable dosing, which precludes the need for routine coagulation monitoring in the general population. However, in patients with NS, concerns exist about optimal dosage of DOACs and their clinical risk/benefit ratio. DOACs are highly protein bound, and hypoalbuminemia could alter blood levels of DOAC with higher free drug levels, precluding possible safety issues. Furthermore, in NS, factor X levels may vary influencing the clinical impact of DOAC¹⁵

Moreover, thromboprophylaxis interest in NS has not been proven in large randomized controlled trials. Evidence is only based on case reports, case series and retrospective studies using heparin and warfarin as anticoagulants. A recent study by Kelddal and colleagues⁵ included 79 patients, of which 44 were treated with low molecular weight heparine (LMWH) and/or warfarin compared to 35 patients without anticoagulation. Four among the 35 patients without thromboprophylaxis presented a VTE but no patient in the prophylaxis group had thrombosis.⁵ Selection bias cannot be excluded since patients without treatment had a higher serum albumin level and no propensity score was used to account for the covariates that could predict receiving the treatment. This study reinforces the clinical interest of thromboprophylaxis in patients with NS. The use of DOACs is tempting and may even obviate the need for concern about heparin resistance due to antithrombin urinary losses.¹

In the current study, we measured for each individual patient Cmin and Cmax anti-Xa apixaban levels. Apixaban was the molecule of choice because of its predictable pharmacokinetic and pharmacodynamic properties that are consistent across the range of different patient populations studied (elderly and those with renal impairment), the fast onset of action, and the low potential for food and drug interactions.¹⁵ We could not compare the levels to previous published studies on Apixaban (ARISTOTLE, AMPLIFY and AMPLIFY-Ext)^{16–18}, since these are the first data gathered in this particular population. However, we notice that the levels are within the therapeutic ranges of the large clinical trials published and observe a normal intra-individual variability of Apixaban levels with only one patient experiencing a new thromboembolic event during follow-up. We must underline the fact that all patients in the study were at high risk of TE events, because of the degree of hypoalbuminemia and predominance of MN.

Lionaki et al¹⁹ confirmed that the severity of hypoalbuminemia is significantly associated with VTE occurrence. These authors have shown that each decrease of 10 g/L in albumin serum level is associated with a two-fold increase of VTE risk. A serum albumin level of 28 g/L was the threshold required for anticoagulation implementation. All of the patients included in our study had a serum albumin level < 25 g/L, with only 3 patients having a serum albumin level above 20 g/L, conferring to this retrospective cohort a significantly high thromboembolic risk.

VTE risk is the highest within the first 6 months after NS onset. The median follow-up time of our study cohort was 11 months [IQR 6–14] and the median duration of anticoagulation was 129 days [IQR 45–224]. Anticoagulation was stopped when serum albumin rose above 20 g/l, with the exception for patients suffering from MN where the threshold was 25 g/l. The follow-up interval was therefore sufficiently large to collect any thrombotic episode

Importantly no minor nor major bleeding adverse events were recorded during follow-up. These findings confirm and extend that anticoagulation with DOACs are safe and well tolerated in patients with severe NS.

Weaknesses of the study were its uncontrolled monocentric historical cohort design, the limited number of patients and the lack of standard of care comprising heparin and/or warfarin arm.²¹

To the best of our knowledge this is the first study that measured apixaban levels in patients with NS and where VTE episodes were carefully recorded in the follow-up. We were able to show the encouraging benefit/risk ratio of apixaban in this particular clinical setting in very high risk patients. Apixaban seems very safe in patients with NS with no bleeding and very effective regarding thrombosis occurrence during a long follow-up. The sole thrombotic episode with PE was reported in a patient with a doubtful compliance.

All these data suggest that thromboprophylaxis in patients suffering from severe NS could be simpler and safer and efficacious with apixaban. Further large multicenter randomized, controlled trials should be conducted to confirm these encouraging results.

Conclusions

The present study shows that patients, suffering from severe NS under anticoagulant therapy with apixaban had reduced risk of venous and arterial TE compared to patients previously described in the literature, without increased risk of bleeding.

List Of Abbreviations

CKD
chronic kidney disease
CKD-Epi
Chronic Kidney Disease Epidemiology Collaboration
Cmin
minimal blood concentration (trough level)
Cmax
maximum blood concentration
DOAC
direct oral anticoagulants

DVT
deep vein thrombosis
eGFR
estimated glomerular filtration rate
FSGS
focal and segmental glomerulosclerosis
IQR
interquartile range
KDIGO
Kidney disease improving global outcomes
LDL
low density lipoprotein
LMWH
low molecular weight heparin
MCS
minimal change disease
MN
membranous nephropathy
NS
nephrotic syndrome
PE
pulmonary embolism
RVT
renal vein thrombosis
SD
standard deviation
TE
thromboembolic events
VTE
venous thromboembolic event

Declarations

Ethics approval and consent to participate

In accordance with *French law*, no ethics committee's oversight was *required* as the design of the *study* was strictly *observational and retrospective*. Patients' information has been anonymized and de-identified before the extraction for analysis. The study was carried out in accordance with ethical guidelines of the Commission nationale de l'informatique et des libertés (CNIL N° 903188). Informed consent was obtained from all the participants whose data is used in the study.

Consent for publication

Not applicable.

Competing interests

There is no conflict of interest among the authors.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

Not applicable

Authors' contributions

Dr Eleonore Ponlot created the dataset. Dr Tess Van Meerhaeghe completed and statistically analyzed the dataset and drafted the manuscript. Pr Jean-Jacques Boffa and Pr Elalamy revised the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgements

Not applicable

References

1. Kerlin BA, Ayoob R, Smoyer WE: Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. *Clin J Am Soc Nephrol* 2012;7: 513–520,
2. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. *Kidney Int.* 2012; 81:190–5.
3. Gyamlani G, Molnar MZ, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. *Nephrol Dial Transplant.* 2017; 32:157–64.
4. Ismael G, Mircescu G, Ditoiu AV, Tacu BD, Jurubita R, Harza M. Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: focus on haemostasis-related parameters. *Int Urol Nephrol.* 2014; 46:787–792.
5. Mahmoodi BK, Ten Kate MK, Waanders F, Veeger NJ, Brouwer JL, Vogt L, Navis G, van der Meer J: High absolute risks and predictors of venous and arterial thromboembolic events in patients with nephrotic syndrome: Results from a large retrospective cohort study. *Circulation.* 2008;117: 224–230.

6. Kelddal S, Nykjaer KM, Gregersen JW, Birn H. Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications. *BMC Nephrology*. 2019; 20:139.
7. Medjeral-Thomas N, Ziaj S, Condon M, Galliford J, Levy J, Cairns T, Griffith M. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. *Clin J Am Soc Nephrol*. 2014; 9:478–83.
8. Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, et al. Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular-weight heparin enoxaparin. *Nephron*. 1995; 69:20–8.
9. Sexton D, De Freitas D, Little MA, et al. Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome. *Kidney Int Rep*. 2018;3(4):784–93
10. Han THC, Thet Z. Warfarin vs. new oral anticoagulant in primary adult nephrotic syndrome associated venous thromboembolism. *Nephrology*. 2017; 22:64
11. Kamran HEF, Khalil Q, Bates J, Morse M. Venous and arterial thromboses in nephrotic syndrome: Where only warfarin has walked. *J Gen Int Med*. 2016:31
12. Zhang L, Zhang H, Zhang J, et al. Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study. *Exp Ther Med*. 2018;15: 739–44.
13. Dupree LH, Reddy P. Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability. *Ann Pharmacother*. 2014; 48:1655–58.
14. Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. *World J Methodol*. 2015;5:212–215.
15. Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. *Clin Pharmacokinet*. 2019; 58:1265–1279.
16. Granger CB, Alexander JH, McMurray JJV, Lopes RD, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2011; 365:981–992
17. Agnelli G, Buller HR, Cohen AC, Curto M et al. Oral Apixaban for the treatment of acute venous thromboembolism. *N Eng J Med*. 2013; 369:799–808.
18. Agnelli G, Buller HR, Cohen A, Curto M et al. Apixaban for Extended Treatment of Venous Thromboembolism. *N Eng J Med*. 2013; 368:699–708.
19. Lionaki S, Derebail V, Hogan SL, Barbour S, Lee T, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN. Venous Thromboembolism in patients with membranous nephropathy. *Clin J Am Soc Nephrol*. 2012;7: 43–51.
20. Wongyung B, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. *Clinical Pharmacokinetics*. 2019; 58:1265–1279.

Figures

Figure 1

Apixaban trough Cmin and Cmax levels (2h after ingestion) are shown for patients on Apixaban 5 mg bid.

Figure 2

Apixaban trough Cmin and Cmax levels (2h after ingestion) are shown for patients on Apixaban 2.5 mg bid.